Abstract
Hemagglutinating virus of Japan (HVJ) is a mouse parainfluenza virus which is not pathogenic for humans, and has a cell fusion activity. Irradiation of HVJ by ultraviolet light causes the RNA genome to fragment into short RNA but still keeps the envelope intact. Resulting HVJ envelope (HVJ -E) has a cell-fusion activity but lacks a replication activity. HVJ-E fused with prostate cancer cells via GD1a, and fragmented RNA genome induced prostate cancer cell apoptosis. HVJ-E also enhanced antitumor response via dendritic cells in vivo. In a phase I/II clinical trial for men with castration-resistant prostate cancer (CRPC), HVJ-E was injected directly into the prostate followed by subcutaneous injections of HVJ-E. HVJ-E treatment for CRPC patients was feasible, and the PSA levels of a subgroup of patients responded. HVJ-E therapy could be an innovative immune therapy for prostate cancer with an acceptable safety profile.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fujimoto N. Novel agents for castration-resistant prostate cancer: early experience and beyond. Int J Urol. 2016;23:114–21.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–93.
Taguchi S, Fukuhara H, Homma Y, Todo T. Current status of clinical trials assessing oncolytic virus therapy for urological cancers. Int J Urol. 2017;24:342–51.
Saga K, Kaneda Y. Oncolytic Sendai virus-based virotherapy for cancer: recent advances. Oncol Virother. 2015;4:141–7.
Curran J, Kolakofsky D. Replication of paramyxoviruses. Adv Virus Res. 1999;54:403–22.
Asano A, Asano K. Viral proteins in cell fusion. Tokai J Exp Clin Med. 1982;7(Suppl):193–6.
Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today. 1999;5:298–303.
Suzuki H, Kurooka M, Hiroaki Y, Fujiyoshi Y, Kaneda Y. Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Lett. 2008;582(9):1325.
Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 2007;67:227–36.
Fujihara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother. 2008;57:73–84.
Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101–5.
Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev. Immunol. 2008;8:559–68.
Hatano K, Miyamoto Y, Nonomura N, Kaneda Y. Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells. Int J Cancer. 2011;129:1838–47.
Li L, Zhang J, Jin B, Block ER, Patel JM. Nitric oxide upregulation of caspase-8 mRNA expression in lung endothelial cells: role of JAK2/STAT-1 signaling. Mol Cell Biochem. 2007;305:71–7.
Fujita K, Nakai Y, Kawashima A, Ujike T, Nagahara A, Nakajima T, et al. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E to castration resistant prostate cancer patients. Cancer Gene Ther. 2017;24(7):277–81.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7:52810–7.
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813–21.
Takehara Y, Satoh T, Nishizawa A, Saeki K, Nakamura M, Masuzawa M, et al. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. Clin Immunol. 2013;149:1–10.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Fujita, K., Kaneda, Y., Nonomura, N. (2018). A New Approach to Castration-Resistant Prostate Cancer Using Inactivated Virus. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_42
Download citation
DOI: https://doi.org/10.1007/978-981-10-7013-6_42
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7012-9
Online ISBN: 978-981-10-7013-6
eBook Packages: MedicineMedicine (R0)